Payer Pushback and Negotiation Readiness

Client Question A small biotech sought to assess whether a cost-based pricing pathway could be credibly pursued in Japan, despite the presence of multiple potentially relevant comparators that risked anchoring the product under the similar-efficacy pricing method. Our Approach We conducted a structured comparator landscape and precedent analysis, mapping all relevant NHI-listed products against the evaluation logic applied by the Drug Pricing Organization. Potential differentiators were assessed across: • Therapeutic equivalence and substitutability • Patient segmentation arguments • Innovation versus incremental positioning • Historical premium and designation precedents We modelled alternative pricing designation scenarios and pressure-tested the arguments with former Chuikyo experts to evaluate the likelihood of avoiding comparator anchoring and the evidentiary threshold required to sustain a cost-based rationale. Outcome We delivered a clear feasibility and risk assessment of the cost-based pathway, identifying: • The probability of comparator designation • Differentiation arguments most likely to withstand DPO scrutiny • Evidence priorities required to support non-comparability • Implications for long-term pricing sustainability This enabled the client to align its development and evidence strategy with Japan’s practical pricing decision dynamics.